| Q34754663 | A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis |
| Q37256808 | Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation |
| Q35751017 | Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells |
| Q46060618 | Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro |
| Q40491709 | Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias |
| Q35058707 | Advanced-phase chronic myeloid leukemia |
| Q38342295 | Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells. |
| Q37974490 | BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. |
| Q42277539 | Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling |
| Q39503233 | Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment |
| Q35828737 | Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease |
| Q92463214 | Bosutinib for the Treatment of Philadelphia Chromosome-Positive Leukemias |
| Q35749778 | Changing picture of cellular drug resistance in human leukemia |
| Q40505693 | Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. |
| Q34268535 | Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment |
| Q35111716 | Clinical Applications of BCR-ABL Molecular Testing in Acute Leukemia |
| Q34075619 | Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop |
| Q37847179 | Current status of agents active against the T315I chronic myeloid leukemia phenotype |
| Q56974816 | Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in t |
| Q40687192 | Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs |
| Q93048204 | Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy |
| Q44117835 | Effects of imatinib on bone marrow engraftment in syngeneic mice. |
| Q44598654 | Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). |
| Q45006858 | Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia |
| Q36512142 | Fusion tyrosine kinases: a result and cause of genomic instability |
| Q36017935 | Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis |
| Q46911787 | High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia |
| Q38845834 | How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety |
| Q35058697 | Imatinib alone and in combination for chronic myeloid leukemia |
| Q35870613 | Imatinib as a paradigm of targeted therapies |
| Q58414406 | Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) |
| Q35828742 | Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia |
| Q35816396 | Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance |
| Q44512453 | Imatinib: resisting the resistance |
| Q36323364 | Importance of extra- and intracellular domains of TLR1 and TLR2 in NFkappa B signaling |
| Q37830694 | Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors |
| Q40515641 | Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes |
| Q35022505 | Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. |
| Q40708026 | Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors |
| Q35058694 | Management of chronic myeloid leukemia: targets for molecular therapy |
| Q44373949 | Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. |
| Q36498963 | Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates |
| Q35782565 | Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia |
| Q35567255 | Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias |
| Q38361603 | Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy |
| Q34175760 | Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. |
| Q35849776 | Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results |
| Q29615030 | Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia |
| Q40618806 | Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD–transformed hematopoietic cells |
| Q37574957 | NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. |
| Q90183997 | Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper |
| Q36316166 | Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia |
| Q33902463 | Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation |
| Q37888714 | Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients |
| Q36988579 | Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia |
| Q28083449 | Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy |
| Q37613888 | Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q37862648 | Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives |
| Q36562207 | Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation |
| Q36228062 | Philadelphia positive acute lymphoblastic leukaemia of childhood |
| Q40709933 | Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. |
| Q35875306 | Plasma cell myeloma and leukemia |
| Q40542008 | Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors |
| Q54330255 | Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. |
| Q41872086 | Protein tyrosine kinase panel as a tool for anticancer drug design. |
| Q40507294 | Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells |
| Q40357233 | Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells |
| Q44643495 | Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. |
| Q35128883 | Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back |
| Q35595402 | Resistance to imatinib (Glivec): update on clinical mechanisms |
| Q35839918 | Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells |
| Q36097229 | Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism |
| Q34929139 | STI-571 in chronic myelogenous leukaemia |
| Q34622576 | Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia |
| Q44582795 | Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment |
| Q44572141 | Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia |
| Q35968384 | Strategies to overcome resistance to targeted protein kinase inhibitors |
| Q37971760 | Suppression of autophagy by BCR/ABL. |
| Q44976586 | Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study). |
| Q35847734 | Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance |
| Q37170788 | Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells |
| Q36967858 | The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias |
| Q38829019 | The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment |
| Q36561648 | The role of companion diagnostics in the development and use of mutation-targeted cancer therapies |
| Q44231537 | Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). |